Table 4. Results of phase III studies comparing platinum and non-platinum containing regimens.

Reference	Number	Regimen	Response rate	Median survival	Survival (at year)
Roth et al.23	159	PE	61%	8.6 m	NR
	156	CAV	51%	8.3 m	NR
	162	CAV/PE	59%	8.1 m	NR
	P value		0.175	0.425
Fukuoka24	97	PE	78%	9.9 m	11.5 (2y)
	97	CAV	55%	9.9 m	10.4 (2y)*
	94	CAV/PE	76%	11.8 m	21.4 (2y)*
	P value	<0.01		0.027
Evans4		CAV	63%		Longer for CAV/PE
		CAV/PE	80%
	P value		0.002		0.03
Chut25		Platinum regimens	NR	9.5 m	NR
(Meta-analysis of 21 studies)		Non-platinum regimens	NR	7.1 m
	P value			0.04
Pujol26	1814	Platinum	OR=1.35	NR	0.8 (1y)
(Meta-analysis of 19 studies)	2240	Non-platinum		NR	Death OR
	P value		<0.0001		0.002
Sundstrom et al.27	218	PE	NR	14.5 m	14% (2y)
	218	CEV	NR	9.7 m	6% (2y)
	P value			(Limited disease)	0.0004
				0.001
Thatcher28	203	ICE-V	83%	15.6 m	20% (2y)
	199	CDE or PE	80%	11.6 m	11% (2y)
	P value		NR	0.026	NR
Johnson29	72	CAV+(PE×2)	NR	21.1 m	44% (2y)
	79	CAV	NR	13.2 m	26% (2y)
	P value			0.028	0.028
Beith30	50	PE	76%	52 w	NR
	54	PE+(CAV)	NR	54 w	NR
	P value			0.636
Mascaux31		Platinum			NR
Meta-analysis of 31 studies		Non-platinum		HR=0.61	NR
	P value			95% CI (0.57–0.66)
White32	59	CAV	38%	17 w	12% (1y)
	60	Carboplatin	25%	15.9 w	6% (1y)
	P value		0.15	NS	0.8

ICE-V, ifosfamide, cisplatin, etoposide, vincristine; CDE, cyclophosphamide, doxorubicin, etoposide; CAV, cyclophosphamide, adriamycin, vincristine; PE, cisplatin, etoposide;

^*P value=0.059.